Overview

Safety and Efficacy Study of Centanafadine Sustained-Release (CTN SR) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

Status:
Completed

Trial end date:
2016-05-01

Target enrollment:

Participant gender:

Summary

This is a Phase IIb, randomized, double-blind, multicenter, 2-period, 2-treatment, crossover study to evaluate safety, efficacy, and duration of efficacy of CTN SR BID target total daily dose (TDD) 400 mg compared with placebo in adults with ADHD.

Phase:

Phase 2

Details

Lead Sponsor:

Neurovance, Inc.
Otsuka Pharmaceutical Development & Commercialization, Inc.